Pfizer buys back into obesity drug chase with $4.9B Metsera deal

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: Pfizer is back in the obesity drug chase, announcing Monday it will pay $4.9 billion, and potentially more, to buy Metsera and its portfolio of weight loss medicines. Per deal terms, Pfizer will pay $47.50 for each Metsera share, more than double the $18 price the company debuted at following an initial public offering in January. Metsera shareho ...